EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China

Dan Li, Jie Yang, Xueying Wang, Lin Yang, Rong Luo, Shaoping Huang iD

Brain and Behavior · 2024

DOI: 10.1002/brb3.3630 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Brain and Behavior, 2024. Verfasst von Dan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Oligonucleotides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Plan of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was based on a retrospective clinical observational cohort study of a two‐center application of nusinersen in China to evaluate the clinical efficacy and adverse effects of nusinersen in the treatment of SMA (spinal muscular atrophy) Types 1–3.

Methods

Clinical data from children with clinically and genetically confirmed 5qSMA from a double center in western China (the Second Affiliated Hospital of Xi'an Jiaotong University and the Second Hospital of West China of Sichuan University). All children were younger than 18 years of age. Patients were assessed for motor function and underwent blood and fluid tests before each nusinersen injection.

Results

At 14‐month follow‐up, 100% of children had improved their HFMSE (Hammersmith Functional Motor Scale Expanded) score, 83.6% had improved their CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) score, and 66.6% had improved their RULM (Revised Upper Limb Module) score by ≥3 points from baseline, and their 6MWT (6‐min walk test) was 216.00 ± 52.08 m longer than at baseline. The age of the child at the start of treatment was negatively correlated with the clinical efficacy of nusinersen; the younger the child, the better the response to treatment. No significant adverse effects affecting the treatment and quality of life of the child were observed during the treatment of SMA with nusinersen.

Conclusion

This study concluded that nusinersen is clinically beneficial for children with SMA in western China, with mild adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesHumansMaleFemaleChild, PreschoolChinaRetrospective StudiesChildInfantMuscular Atrophy, SpinalTreatment OutcomeAdolescentSpinal Muscular Atrophies of Childhood

Stichwörter der Autor:innen

SMAclinical effectmotor functionnusinersen

Substanzen

nusinersenOligonucleotides

Autor:innen und Institutionen

  • Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Shaoping Huang

Förderung

  • Key R&D Plan of Shaanxi Province

Zitieren

APA

Li, D., Yang, J., Wang, X., Yang, L., Luo, R., & Huang, S. (2024). Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China. Brain and Behavior. https://doi.org/10.1002/brb3.3630

Vancouver

Li D, Yang J, Wang X, Yang L, Luo R, Huang S. Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China. Brain and Behavior. 2024. doi:10.1002/brb3.3630

BibTeX
@article{Li2024,
  author = {Li, Dan and Yang, Jie and Wang, Xueying and Yang, Lin and Luo, Rong and Huang, Shaoping},
  title = {Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China},
  journal = {Brain and Behavior},
  year = {2024},
  doi = {10.1002/brb3.3630}
}
Kostenlos starten →